Differences in BCL-XL expression and STAT5 phosphorylation in chronic myeloid leukaemia patients

European Journal of Haematology

Volumn 72, Issue 4, 2004, Pages 231-238

  Gutiérrez Castellanos, Sergio ^a,b,d   Cruz, Miguel ^c   Rabelo, Laura ^a   Godínez, Rocio ^a   Reyes Maldonado, Elba ^b   Riebeling Navarro, Carlos ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d NONE   (Mexico)

Author keywords

BCR ABL; CML; Phosphorylation; STAT5

Indexed keywords

BCR ABL PROTEIN; BETA ACTIN; COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN BCL XL; STAT5 PROTEIN;

ADULT; ARTICLE; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA; MALE; MALIGNANT TRANSFORMATION; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 1642483699     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00201.x     Document Type: Article

References (31)

1. DENINGER MWN, GOLDMAN JM, MELO JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
2. NIEBOROWSKA-SKORSKA M, WASIK MA, SLUPIAKEK A, SALOMONI P, KITAMURA T, CALABRETTA B, SKORSKI T. Signal transducer and activator of transcription (STAT)5 activation by BCR-ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR-ABL and is required for leukemogenesis. J Exp Med 1999;189:1229-1242.
3. ILARIA RI, VAN ETTEN RA. P210 and 190BCR-ABL induce tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-31710.
4. DARNELL JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
5. LEONARD WJ, O'SHEA JJ. Jaks and Stats: biological implications. Annu Rev Immunol 1998;16:293-322.
6. DE GROOT RP, RAAIJMAKERS JAM, LAMMERS JWJ, JOVE R, KOENDERMAN L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999;94:1108-1112.
7. GRIMLEY PM, DONG F, RUI H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999;10:131-157.
8. L gene expression by STAT5 in a bone marrow cell line. Oncogene 1999;18:4191-4199.
9. L. J Exp Med 2000;191:977-984.
10. L by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev 1998;12:2475-2487.
11. CARLESSO N, FRANK DA, GRIFFIN JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR-ABL. J Exp Med 1996;183:811-820.
12. CHAI SK, NICHOLS GL, ROTHMAN P. Constitutive activation of Jaks and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997;159:4720-4728.
13. SHUAI K, HALPERN J, TEN HOEVE J, RAO X, SAWYERS CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-254.
14. KANTARJIAN HM, DEISSEROTH A, KURZROCK R, ESTROV Z, TALPAZ M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
15. YAGISAWA M, SAEKI K, OKUMA E, et al. Signal transduction pathways in normal human monocytes stimulated by cytokines and mediators: Comparative study with normal human neutrophil or transformed cells and the putative roles in functionality and cell biology. Exp Hematol 1999;27:1063-1076.
16. GORDON JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol 1991;201:477-482.
17. THOMPSON JD, BRODSKY I, YUNIS JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992;79:1629-1635.
18. MELBY PC, DARNELL BJ, TRYON VV. Quantitative measurement of human cytokine gene expression by polymerase chain reaction. J Immunol Meth 1993;159:235-244.
19. L. Blood 1996;87:3837-3843
20. MENDOZA L, OROZCO E, RODRÍGUEZ MA, et al. Ehp53, an Entamoeba histolytica protein, ancestor of the mammalian tumor suppressor p53. Microbiology 2003;149:885-893.
21. OETZEL C, JONULEIT T, GÖTZ A, et al. The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 2000;6:1958-1968.
22. NIEBOROWSKA-SKORSKA M, SLUPIANEK A, SKORKI T. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells. Oncogene 2000;19:4117-4124.
23. KIESLINGER M, WOLDMAN I, MORIGGL R, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000;14:232-244.
24. PEREGO RA, COSTANTINI M, CORNACCHINI G, et al. The possible influences of b2a2 and b3a2 Bcr/Abl protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000;36:1395-1401.
25. XIA Z, SAIT SNJ, BAER MR, et al. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 2001;25:473-482.
26. LEE C, PIAZZA F, BRUTSAERT S, et al. Characterization of the Stat5 protease. J Biol Chem 1999;274:26767-26775.
27. XIA Z, SALZLER RR, KUNZ DP, BAER MR, KAZIM L, BAUMANN H, WETZLER M. A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator or transcription proteins in acute myeloid leukemia blasts. Cancer Res 2001;61:1747-1753.
28. WANG D, STRAVOPODIS D, TEGLUND S, KITAZAWA J, IHLE JN. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 1996;16:6141-6148.
29. COFFER PJ, KOENDERMAN L, DE GROOT RP. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000;19:2511-2522.
30. DE GROOT RP, RAAIJMAKERS JAM, LAMMERS JWJ, KOENDERMAN L. STAT5-dependent cyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Research Commun 2000;3:299-305.
31. L gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. Haematologica 2001;86:470-477.